PDF(Pubmed)
Abstract：
18F-fluorodeoxyglucose (FDG) and 18F-sodium fluoride (NaF) represent emerging PET tracers used to assess atherosclerosis-related inflammation and molecular calcification, respectively. By localizing to sites with high glucose utilization, FDG has been used to assess myocardial viability for decades, and its role in evaluating cardiac sarcoidosis has come to represent a major application. In addition to determining late-stage changes such as loss of perfusion or viability, by targeting mechanisms present in atherosclerosis, PET-based techniques have the ability to characterize atherogenesis in the early stages to guide intervention. Although it was once thought that FDG would be a reliable indicator of ongoing plaque formation, micro-calcification as portrayed by NaF-PET/CT appears to be a superior method of monitoring disease progression. PET imaging with NaF has the additional advantage of being able to determine abnormal uptake due to coronary artery disease, which is obscured by physiologic myocardial activity on FDG-PET/CT. In this review, we discuss the evolving roles of FDG, NaF, and other PET tracers in cardiac molecular imaging.
摘要：
18F-氟脱氧葡萄糖（FDG）和18F-氟化钠（NaF）代表新兴的PET示踪剂，用于评估动脉粥样硬化相关的炎症和分子钙化，分别。通过定位到葡萄糖利用率高的地点，几十年来，FDG一直被用来评估心肌的活力，它在评估心脏结节病中的作用已经成为一个主要的应用。除了确定晚期变化，如灌注或生存力的丧失，通过动脉粥样硬化中存在的靶向机制，基于PET的技术具有在早期阶段表征动脉粥样硬化形成以指导干预的能力。尽管曾经有人认为FDG将是正在进行的斑块形成的可靠指标，NaF-PET/CT所描绘的微钙化似乎是监测疾病进展的一种较好方法。使用NaF的PET成像具有能够确定冠状动脉疾病引起的异常摄取的额外优势，FDG-PET/CT上的生理心肌活动掩盖了这一点。在这次审查中,我们讨论了FDG不断演变的角色，NaF,和其他PET示踪剂在心脏分子成像。
